Inclusion Criteria:

- Histologically or cytologically confirmed Cancer.

- Age ≦ 80 years old and ≧ 18 years old.

- Eastern Cooperative Oncology Group(ECOG) performance status of 0-2.

- Adequate organ function, including followings Hepatic： Total bilirubin level ≦1.5 x
UNL, GOT and GPT ≦ 2.5 x UNL if no liver metastasis; GOT and GPT ≦ 5 x UNL if liver
metastasis. Renal： Creatinine level＜ 1.5 milligram per deciliter or Estimated
creatinine clearance(CCr) ≧ 60 milliliter per minute (CCr is estimated by
Cockcroft-Gault formula, as appendix II)

- Estimated life expectancy of at least 12 weeks.

- Written(signed) Informed Consent

- Ever treated and poor tolerance with platinum-based or anthracycline- based
regimen, likely nausea and vomiting.

Exclusion Criteria:

- Prior participation in any investigational drug study within 28 days

- Active uncontrolled infections or human immunodeficiency virus(HIV) infection

- Significant concurrent medical diseases, such as congestive heart failure, unstable
angina, acute or recent myocardial infarction( 6 months before randomization),
chronic obstructive pulmonary disease with frequent exacerbation, chronic renal
diseases (estimated CCr 60 milliliter per minute), uncontrolled diabetes,
uncontrolled hypertension, recent cerebrovascular disease episode( 6 months before
randomization )

- With clinically significant Gastrointestinal disorder (e.g. bleeding, inflammation,
obstruction or diarrhea)

- Psychiatric disorders that would compromise the patient's compliance or decision.

- Pregnancy or breast feeding.

- Known hypersensitivity to the component of investigational drugs.

- Known or suspected Gilbert's syndrome

- Poor compliance